Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ANIK Anika Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: ANIK
Price (delayed)
$10.93
Market cap
$156.75M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.87
Enterprise value
$126.94M
Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Anika Therapeutics partners with clinicians to understand what they need
Highlights
The net income rose by 26% year-on-year
The company's EPS rose by 26% YoY
ANIK's equity is down by 29% year-on-year and by 3.6% since the previous quarter
The company's gross profit fell by 16% YoY and by 13% QoQ
Key stats
What are the main financial stats of ANIK
Market
Valuations
Earnings
Shares outstanding
14.34M
Market cap
$156.75M
Enterprise value
$126.94M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.04
Price to sales (P/S)
1.48
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.2
Revenue
$105.55M
Gross profit
$66.05M
Operating income
-$4.32M
Net income
-$56.74M
EBIT
-$53.39M
EBITDA
-$43.57M
Free cash flow
-$3.95M
Per share
Balance sheet
Liquidity
EPS
-$3.87
EPS diluted
-$3.87
Free cash flow per share
-$0.28
Book value per share
$10.47
Revenue per share
$7.38
TBVPS
$12.65
Total assets
$190.61M
Total liabilities
$42.21M
Debt
$23.56M
Equity
$148.4M
Working capital
$84.61M
Debt to equity
0.16
Current ratio
5.73
Quick ratio
4.21
Net debt/EBITDA
0.68
Margins
Efficiency
Dividend
EBITDA margin
-41.3%
Gross margin
62.6%
Net margin
-53.8%
Operating margin
-4.1%
Return on assets
-25.6%
Return on equity
-32.8%
Return on invested capital
-34.6%
Return on capital employed
-30.9%
Return on sales
-50.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ANIK stock price
How has the Anika Therapeutics stock price performed over time
Intraday
-3.02%
1 week
-3.7%
1 month
-11.93%
1 year
-57.91%
YTD
-33.6%
QTD
-27.28%
Financial performance
How have Anika Therapeutics's revenue and profit performed over time
Revenue
$105.55M
Gross profit
$66.05M
Operating income
-$4.32M
Net income
-$56.74M
Gross margin
62.6%
Net margin
-53.8%
Anika Therapeutics's operating margin has plunged by 142% YoY but it has increased by 4.7% from the previous quarter
Anika Therapeutics's operating income has plunged by 140% YoY but it has increased by 15% from the previous quarter
The net income rose by 26% year-on-year
Anika Therapeutics's net margin has increased by 22% YoY but it has decreased by 14% QoQ
Price vs fundamentals
How does ANIK's price correlate with its fundamentals
Growth
What is Anika Therapeutics's growth rate over time
Valuation
What is Anika Therapeutics stock price valuation
P/E
N/A
P/B
1.04
P/S
1.48
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.2
The company's EPS rose by 26% YoY
ANIK's price to book (P/B) is 39% less than its 5-year quarterly average of 1.7 and 39% less than its last 4 quarters average of 1.7
ANIK's equity is down by 29% year-on-year and by 3.6% since the previous quarter
ANIK's P/S is 55% below its 5-year quarterly average of 3.3 and 45% below its last 4 quarters average of 2.7
The revenue has contracted by 12% from the previous quarter and by 6% YoY
Efficiency
How efficient is Anika Therapeutics business performance
The company's return on sales rose by 21% YoY but it fell by 15% QoQ
The ROIC is up by 11% year-on-year but it is down by 9% since the previous quarter
The return on assets has declined by 9% since the previous quarter
Anika Therapeutics's ROE has decreased by 9% from the previous quarter and by 3.1% YoY
Dividends
What is ANIK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ANIK.
Financial health
How did Anika Therapeutics financials performed over time
The total assets has decreased by 28% YoY and by 6% QoQ
Anika Therapeutics's quick ratio has increased by 24% from the previous quarter and by 19% YoY
Anika Therapeutics's debt is 84% lower than its equity
ANIK's equity is down by 29% year-on-year and by 3.6% since the previous quarter
The debt to equity is up by 23% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.